怀孕
疾病
医学
风湿性疾病
儿科
低出生体重
自身免疫性疾病
重症监护医学
免疫学
内科学
遗传学
生物
作者
Laura Andréoli,Jeanette Andersen,Tadej Avčin,Christina Chambers,Elisa M Fazzi,Neil Marlow,Nico Wulffraat,Angela Tincani
标识
DOI:10.1016/s2665-9913(24)00096-1
摘要
Maternal autoimmune rheumatic diseases can influence the outcomes of children through several life stages. During pregnancy, maternal inflammation and autoantibodies can hinder fetal development and lead to growth restriction, preterm birth, and low birth weight; prematurity, especially at extreme gestational ages, can in turn impair future child health. Treatment with compatible immunomodulatory drugs and preventive medications aims to keep maternal disease under control and minimise the risk of adverse pregnancy outcomes. However, concerns have been raised about the effects of immunomodulatory drugs on neonatal conditions (ie, the risk of serious infections, inadequate responses to vaccinations, and organ toxicity) and long-term outcomes (metabolic and cardiovascular problems and neurodevelopmental disorders). Among the unmet needs of parents with autoimmune rheumatic diseases, there is the estimation of risk for the children to develop autoimmune disorders and the need for reassurance about parenting capacity while living with a chronic condition. This Series paper provides a comprehensive overview of the literature and guidance on discussing these topics with patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI